Selected research
Market Structure
Global Anti-α4β7 Integrin Monoclonal Antibody Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Anti-α4β7 Integrin Monoclonal Antibody market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Anti-α4β7 Integrin Monoclonal Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Anti-α4β7 Integrin Monoclonal Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Anti-α4β7 Integrin Monoclonal Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Anti-α4β7 Integrin Monoclonal Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Anti-α4β7 Integrin Monoclonal Antibody include Biogen, Novartis, Sandoz and Takeda, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Anti-α4β7 Integrin Monoclonal Antibody market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Anti-α4β7 Integrin Monoclonal Antibody and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Anti-α4β7 Integrin Monoclonal Antibody sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Anti-α4β7 Integrin Monoclonal Antibody market size, projected growth trends, production technologies, key applications, and end-use industries.
Anti-α4β7 Integrin Monoclonal Antibody Segment by Company
Biogen
Novartis
Sandoz
Takeda
Anti-α4β7 Integrin Monoclonal Antibody Segment by Type
Natalizumub
Vedolizumab
Anti-α4β7 Integrin Monoclonal Antibody Segment by Application
Inflammatory Bowel Disease (IBD)
Multiple Sclerosis (MS)
Other
Anti-α4β7 Integrin Monoclonal Antibody Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-α4β7 Integrin Monoclonal Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti-α4β7 Integrin Monoclonal Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-α4β7 Integrin Monoclonal Antibody.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Anti-α4β7 Integrin Monoclonal Antibody market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Anti-α4β7 Integrin Monoclonal Antibody manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Anti-α4β7 Integrin Monoclonal Antibody in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Anti-α4β7 Integrin Monoclonal Antibody in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Natalizumub
- Vedolizumab
Applications
- Inflammatory Bowel Disease (IBD)
- Multiple Sclerosis (MS)
- Other
Companies covered
- Biogen
- Novartis
- Sandoz
- Takeda
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Anti-α4β7 Integrin Monoclonal Antibody Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Anti-α4β7 Integrin Monoclonal Antibody Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Anti-α4β7 Integrin Monoclonal Antibody Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Anti-α4β7 Integrin Monoclonal Antibody Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Anti-α4β7 Integrin Monoclonal Antibody Market Dynamics
- 2.1 Anti-α4β7 Integrin Monoclonal Antibody Industry Trends
- 2.2 Anti-α4β7 Integrin Monoclonal Antibody Industry Drivers
- 2.3 Anti-α4β7 Integrin Monoclonal Antibody Industry Opportunities and Challenges
- 2.4 Anti-α4β7 Integrin Monoclonal Antibody Industry Restraints
3 Anti-α4β7 Integrin Monoclonal Antibody Market by Manufacturers
- 3.1 Global Anti-α4β7 Integrin Monoclonal Antibody Revenue by Manufacturers (2021-2026)
- 3.2 Global Anti-α4β7 Integrin Monoclonal Antibody Sales by Manufacturers (2021-2026)
- 3.3 Global Anti-α4β7 Integrin Monoclonal Antibody Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Anti-α4β7 Integrin Monoclonal Antibody Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Anti-α4β7 Integrin Monoclonal Antibody Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Anti-α4β7 Integrin Monoclonal Antibody Manufacturers, Product Type & Application
- 3.7 Global Anti-α4β7 Integrin Monoclonal Antibody Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Anti-α4β7 Integrin Monoclonal Antibody Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Anti-α4β7 Integrin Monoclonal Antibody Players Market Share by Revenue in 2025
- 3.8.3 2025 Anti-α4β7 Integrin Monoclonal Antibody Tier 1, Tier 2, and Tier 3
4 Anti-α4β7 Integrin Monoclonal Antibody Market by Type
- 4.1 Anti-α4β7 Integrin Monoclonal Antibody Type Introduction
- 4.1.1 Natalizumub
- 4.1.2 Vedolizumab
- 4.2 Global Anti-α4β7 Integrin Monoclonal Antibody Sales by Type
- 4.2.1 Global Anti-α4β7 Integrin Monoclonal Antibody Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Anti-α4β7 Integrin Monoclonal Antibody Sales by Type (2021-2032)
- 4.2.3 Global Anti-α4β7 Integrin Monoclonal Antibody Sales Market Share by Type (2021-2032)
- 4.3 Global Anti-α4β7 Integrin Monoclonal Antibody Revenue by Type
- 4.3.1 Global Anti-α4β7 Integrin Monoclonal Antibody Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Anti-α4β7 Integrin Monoclonal Antibody Revenue by Type (2021-2032)
- 4.3.3 Global Anti-α4β7 Integrin Monoclonal Antibody Revenue Market Share by Type (2021-2032)
5 Anti-α4β7 Integrin Monoclonal Antibody Market by Application
- 5.1 Anti-α4β7 Integrin Monoclonal Antibody Application Introduction
- 5.1.1 Inflammatory Bowel Disease (IBD)
- 5.1.2 Multiple Sclerosis (MS)
- 5.1.3 Other
- 5.2 Global Anti-α4β7 Integrin Monoclonal Antibody Sales by Application
- 5.2.1 Global Anti-α4β7 Integrin Monoclonal Antibody Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Anti-α4β7 Integrin Monoclonal Antibody Sales by Application (2021-2032)
- 5.2.3 Global Anti-α4β7 Integrin Monoclonal Antibody Sales Market Share by Application (2021-2032)
- 5.3 Global Anti-α4β7 Integrin Monoclonal Antibody Revenue by Application
- 5.3.1 Global Anti-α4β7 Integrin Monoclonal Antibody Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Anti-α4β7 Integrin Monoclonal Antibody Revenue by Application (2021-2032)
- 5.3.3 Global Anti-α4β7 Integrin Monoclonal Antibody Revenue Market Share by Application (2021-2032)
6 Global Anti-α4β7 Integrin Monoclonal Antibody Sales by Region
- 6.1 Global Anti-α4β7 Integrin Monoclonal Antibody Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Anti-α4β7 Integrin Monoclonal Antibody Sales by Region (2021-2032)
- 6.2.1 Global Anti-α4β7 Integrin Monoclonal Antibody Sales by Region (2021-2026)
- 6.2.2 Global Anti-α4β7 Integrin Monoclonal Antibody Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Anti-α4β7 Integrin Monoclonal Antibody Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Anti-α4β7 Integrin Monoclonal Antibody Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Anti-α4β7 Integrin Monoclonal Antibody Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Anti-α4β7 Integrin Monoclonal Antibody Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Anti-α4β7 Integrin Monoclonal Antibody Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Anti-α4β7 Integrin Monoclonal Antibody Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Anti-α4β7 Integrin Monoclonal Antibody Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Anti-α4β7 Integrin Monoclonal Antibody Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Anti-α4β7 Integrin Monoclonal Antibody Revenue by Region
- 7.1 Global Anti-α4β7 Integrin Monoclonal Antibody Revenue by Region
- 7.1.1 Global Anti-α4β7 Integrin Monoclonal Antibody Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Anti-α4β7 Integrin Monoclonal Antibody Revenue by Region (2021-2026)
- 7.1.3 Global Anti-α4β7 Integrin Monoclonal Antibody Revenue by Region (2027-2032)
- 7.1.4 Global Anti-α4β7 Integrin Monoclonal Antibody Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Anti-α4β7 Integrin Monoclonal Antibody Revenue (2021-2032)
- 7.2.2 North America Anti-α4β7 Integrin Monoclonal Antibody Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Anti-α4β7 Integrin Monoclonal Antibody Revenue (2021-2032)
- 7.3.2 Europe Anti-α4β7 Integrin Monoclonal Antibody Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Anti-α4β7 Integrin Monoclonal Antibody Revenue (2021-2032)
- 7.4.2 Asia-Pacific Anti-α4β7 Integrin Monoclonal Antibody Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Anti-α4β7 Integrin Monoclonal Antibody Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Anti-α4β7 Integrin Monoclonal Antibody Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Biogen
- 8.1.1 Biogen Company Information
- 8.1.2 Biogen Business Overview
- 8.1.3 Biogen Anti-α4β7 Integrin Monoclonal Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Biogen Anti-α4β7 Integrin Monoclonal Antibody Product Portfolio
- 8.1.5 Biogen Recent Developments
- 8.2 Novartis
- 8.2.1 Novartis Company Information
- 8.2.2 Novartis Business Overview
- 8.2.3 Novartis Anti-α4β7 Integrin Monoclonal Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Novartis Anti-α4β7 Integrin Monoclonal Antibody Product Portfolio
- 8.2.5 Novartis Recent Developments
- 8.3 Sandoz
- 8.3.1 Sandoz Company Information
- 8.3.2 Sandoz Business Overview
- 8.3.3 Sandoz Anti-α4β7 Integrin Monoclonal Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Sandoz Anti-α4β7 Integrin Monoclonal Antibody Product Portfolio
- 8.3.5 Sandoz Recent Developments
- 8.4 Takeda
- 8.4.1 Takeda Company Information
- 8.4.2 Takeda Business Overview
- 8.4.3 Takeda Anti-α4β7 Integrin Monoclonal Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Takeda Anti-α4β7 Integrin Monoclonal Antibody Product Portfolio
- 8.4.5 Takeda Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Anti-α4β7 Integrin Monoclonal Antibody Value Chain Analysis
- 9.1.1 Anti-α4β7 Integrin Monoclonal Antibody Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Anti-α4β7 Integrin Monoclonal Antibody Production Mode & Process
- 9.2 Anti-α4β7 Integrin Monoclonal Antibody Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Anti-α4β7 Integrin Monoclonal Antibody Distributors
- 9.2.3 Anti-α4β7 Integrin Monoclonal Antibody Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst